{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-23-000004","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.345176+00:00","generated_at":"2026-06-19T23:29:13.593473+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex reports FY22 product revenue $8.93B (+18% YoY); guides FY23 $9.55-$9.7B","bullets":["Full year 2022 product revenue $8.93B, up 18% vs 2021; GAAP net income $3.32B, up 42%.","Q4 product revenue $2.30B (+11% YoY); GAAP diluted EPS $3.15, non-GAAP $3.76.","FY2023 product revenue guidance of $9.55B-$9.7B, implying 7-9% growth.","Exa-cel regulatory submissions validated in EU and UK; US rolling BLA underway.","CF drug TRIKAFTA/KAFTRIO generated $7.69B in FY22, up 35% from $5.70B in FY21."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-23-000004","json":"https://secwatch.observer/filing/0000875320-23-000004.json","markdown":"https://secwatch.observer/filing/0000875320-23-000004.md","text":"https://secwatch.observer/filing/0000875320-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/0000875320-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/vrtx-20230207.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:29:13.593473+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7bb9ffeb35528e9cf6f176e2405234ac5bd35a7c","claim":"VERTEX PHARMACEUTICALS INC / MA reported Three Months Ended December 31, 2022 results: revenue $ 2,303, net income $ 819, EPS $ 3.15. Guidance initiated.","evidence_excerpt":"Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/0000875320-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Three Months Ended December 31, 2022"},{"label":"Revenue","value":"$ 2,303"},{"label":"Net income","value":"$ 819"},{"label":"EPS","value":"$ 3.15"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"89085e1c9cf75752b5693c9753c4931582366f9f","claim":"VERTEX PHARMACEUTICALS INC / MA reported Twelve Months Ended December 31, 2022 results: revenue $ 8,931, net income $ 3,322, EPS $ 12.82. Guidance initiated.","evidence_excerpt":"Product revenues, net $ 2,303 $ 2,073 11% $ 8,931 $ 7,573 18% TRIKAFTA/KAFTRIO $ 2,022 $ 1,693 $ 7,687 $ 5,697 SYMDEKO/SYMKEVI $ 34 $ 80 $ 180 $ 420 ORKAMBI $ 111 $ 147 $ 511 $ 772 KALYDECO $ 136 $ 152 $ 553 $ 684 GAAP operating income $ 1,034 $ 878 18% $ 4,307 $ 2,782 55% Non-GAAP operating income* $ 1,150 $ 997 15% $ 4,793 $ 3,232 48% GAAP net income $ 819 $ 770 6% $ 3,322 $ 2,342 42% Non-GAAP net income* $ 978 $ 777 26% $ 3,855 $ 2,513 53% GAAP net income per share - diluted $ 3.15 $ 3.00 5% $ 12.82 $ 9.01 42%","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532023000004/0000875320-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Twelve Months Ended December 31, 2022"},{"label":"Revenue","value":"$ 8,931"},{"label":"Net income","value":"$ 3,322"},{"label":"EPS","value":"$ 12.82"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}